KR20210087539A - 눈 질환을 치료하기 위한 펩타이드 및 약학적 조성물 - Google Patents

눈 질환을 치료하기 위한 펩타이드 및 약학적 조성물 Download PDF

Info

Publication number
KR20210087539A
KR20210087539A KR1020217018226A KR20217018226A KR20210087539A KR 20210087539 A KR20210087539 A KR 20210087539A KR 1020217018226 A KR1020217018226 A KR 1020217018226A KR 20217018226 A KR20217018226 A KR 20217018226A KR 20210087539 A KR20210087539 A KR 20210087539A
Authority
KR
South Korea
Prior art keywords
compound
formula
substituted
alkyl
arylalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217018226A
Other languages
English (en)
Korean (ko)
Inventor
태곤 백
종윤 최
경욱 민
춘호 박
Original Assignee
주식회사 유유제약
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 유유제약 filed Critical 주식회사 유유제약
Publication of KR20210087539A publication Critical patent/KR20210087539A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Immunology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020217018226A 2018-11-14 2019-11-14 눈 질환을 치료하기 위한 펩타이드 및 약학적 조성물 Ceased KR20210087539A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862767180P 2018-11-14 2018-11-14
US62/767,180 2018-11-14
PCT/IB2019/001220 WO2020099925A2 (en) 2018-11-14 2019-11-14 Peptides and pharmaceutical compositions for treating eye diseases

Publications (1)

Publication Number Publication Date
KR20210087539A true KR20210087539A (ko) 2021-07-12

Family

ID=70732068

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217018226A Ceased KR20210087539A (ko) 2018-11-14 2019-11-14 눈 질환을 치료하기 위한 펩타이드 및 약학적 조성물

Country Status (10)

Country Link
EP (1) EP3880690A4 (https=)
JP (1) JP7522732B2 (https=)
KR (1) KR20210087539A (https=)
CN (1) CN113474356B (https=)
AU (1) AU2019378162B2 (https=)
BR (1) BR112021009341A2 (https=)
MX (1) MX2021005077A (https=)
SG (1) SG11202104178TA (https=)
TW (1) TWI865470B (https=)
WO (1) WO2020099925A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023234703A1 (ko) * 2022-05-31 2023-12-07 주식회사 세네릭스 신규의 d-아미노산 유도체 및 이를 포함하는 약학 조성물

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2766160C2 (ru) 2017-05-17 2022-02-08 Юю Фарма, Инк. Новый пептид и фармацевтический состав для лечения глазного заболевания, содержащий пептид в качестве активного фармацевтического ингредиента
US11613558B2 (en) 2018-11-14 2023-03-28 Yuyu Pharma, Inc. Peptides and pharmaceutical compositions for treating eye diseases
BR112021023477A2 (pt) 2019-05-21 2022-02-15 Eyebio Korea Novo composto peptídico, composição farmacêutica para prevenir ou tratar inflamação, composição de alimento para prevenir ou amenizar a inflamação e composição de cosmético tendo um efeito anti inflamatório
CA3170606A1 (en) * 2020-03-05 2021-09-30 Wonsang YU Treatment of inflammatory diseases with peptides and pharmaceutical compositions
EP4450079A4 (en) * 2021-12-13 2025-12-10 Eyebiokorea Inc COMPOSITION FOR THE TREATMENT OF MACULAR DEGENERATION COMPRISING A NEW PEPTIDE

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037135A (en) * 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
KR101690539B1 (ko) * 2015-07-30 2016-12-29 주식회사 아이바이오코리아 건성안 예방 또는 치료용 약학조성물
EP3539559B1 (en) * 2016-04-08 2020-08-26 Eyebio Korea Collagen type ii alpha-1-based peptide for use in the treatment of macular degeneration
KR101795653B1 (ko) * 2016-05-19 2017-11-09 인제대학교 산학협력단 콜라겐 타입 ii 펩타이드-아플리버셉트의 키메라 단백질을 유효성분으로 함유하는 혈관신생 억제용 조성물
KR20180074928A (ko) * 2016-12-26 2018-07-04 주식회사 아이바이오코리아 건성안 예방 또는 치료용 동물 의약품 조성물
RU2766160C2 (ru) * 2017-05-17 2022-02-08 Юю Фарма, Инк. Новый пептид и фармацевтический состав для лечения глазного заболевания, содержащий пептид в качестве активного фармацевтического ингредиента

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023234703A1 (ko) * 2022-05-31 2023-12-07 주식회사 세네릭스 신규의 d-아미노산 유도체 및 이를 포함하는 약학 조성물
JP2025513314A (ja) * 2022-05-31 2025-04-24 セネリックス カンパニー リミテッド 新規のｄ－アミノ酸誘導体及びこれを含む薬学組成物

Also Published As

Publication number Publication date
WO2020099925A3 (en) 2020-06-25
WO2020099925A2 (en) 2020-05-22
JP7522732B2 (ja) 2024-07-25
CN113474356B (zh) 2024-12-17
SG11202104178TA (en) 2021-05-28
AU2019378162B2 (en) 2025-01-30
JP2022507404A (ja) 2022-01-18
EP3880690A4 (en) 2023-09-13
EP3880690A2 (en) 2021-09-22
CA3119921A1 (en) 2020-05-22
CN113474356A (zh) 2021-10-01
MX2021005077A (es) 2021-08-11
AU2019378162A1 (en) 2021-05-20
TW202031675A (zh) 2020-09-01
TWI865470B (zh) 2024-12-11
BR112021009341A2 (pt) 2021-08-10

Similar Documents

Publication Publication Date Title
TWI865470B (zh) 治療眼睛疾病之肽及醫藥組合物
KR102498428B1 (ko) 신규한 펩타이드 및 이를 유효성분으로 포함하는 안구질환 치료용 약학 조성물
CN107405336A (zh) 作为免疫调节剂的1,3,4‑噁二唑和噻二唑化合物
CN107427476A (zh) 作为免疫调节剂的3‑取代的‑1,2,4‑噁二唑和噻二唑化合物
KR20220149745A (ko) 펩타이드를 이용한 염증성 질환의 치료 및 약학적 조성물
TW201643178A (zh) 在ＭｅＢｍｔ側鏈上經雜環修飾之環孢靈素
US20210198242A1 (en) Biheterocyclic compound
US20230312648A1 (en) Peptides and pharmaceutical compositions for treating eye diseases
CA3119921C (en) Peptides and pharmaceutical compositions for treating eye diseases
RU2819399C2 (ru) Пептиды и фармацевтические композиции для лечения глазных болезней
JP7834361B2 (ja) 置換４－（［１，２，４］トリアゾロ［１，５－ａ］ピリジン－６－イル）チオフェン－２－カルボキサミド誘導体及びその使用
HK40061089A (en) Peptides and pharmaceutical compositions for treating eye diseases
HK40061089B (zh) 用於治疗眼病的肽和药物组合物
HK40017864A (en) Novel peptide and pharmaceutical composition for treatment of eye diseases comprising same novel peptide as active ingredient

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601